The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...

The FINANCIAL — Janssen Pharmaceuticals announced the U.S. Food and Drug Administration has approved XARELTO, an oral anticoagulant, for the treatment of deep vein thrombosis and/or pulmonary embolism ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

September 23, 2011 (London, United Kingdom) — Advisors for the European Medicines Agency (EMA) have paved the way for two new indications for rivaroxaban (Xarelto, Bayer) in Europe. The EMA's ...

Given the medical need for maintenance of anticoagulation in so many medical situations, particularly in cardiovascular patients, and given the many challenges posed for patients and healthcare givers ...

DEAR DR. ROACH: I am an 81-year-old female who has been on Xarelto for years due to my deep vein thrombosis (DVT). I also have an inferior vena cava (IVC) filter. I read that low-dose aspirin (325 mg) ...

NEW YORK (AP) — Johnson & Johnson’s Xarelto received an expanded indication as the Food and Drug Administration on Friday approved the blood thinner both to treat and to reduce the risk of recurrence ...

Dear Dr. Roach: I am an 81-year-old female who has been on Xarelto for years due to my deep vein thrombosis (DVT). I also have an inferior vena cava (IVC) filter. I read that low-dose aspirin (325 mg) ...

For hospitalized COVID-19 patients with a high risk of venous thromboembolism (VTE) and/or elevated D-dimer levels, along with a low risk of bleeding, use of rivaroxaban 10 mg/day for 35 days after ...